2022
DOI: 10.1016/j.jcmg.2022.03.002
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
148
2
4

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 229 publications
(158 citation statements)
references
References 28 publications
4
148
2
4
Order By: Relevance
“…The decrease in PAV (−2.1 vs −0.9% in alirocumab and placebo groups, respectively) in the PCSK9 inhibitor group was greater than that observed in the more stable patients in GLAGOV. A similar finding was observed in the High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS), in which the PAV regression observed with evolocumab was much greater than its effects in GLAGOV (−2.29 vs −0.95%) [51] . The consistent finding of greater plaque regression in acute coronary syndrome patients was observed in the setting of greater plaque burden at baseline.…”
Section: Pcsk9 Inhibitorssupporting
confidence: 80%
See 1 more Smart Citation
“…The decrease in PAV (−2.1 vs −0.9% in alirocumab and placebo groups, respectively) in the PCSK9 inhibitor group was greater than that observed in the more stable patients in GLAGOV. A similar finding was observed in the High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS), in which the PAV regression observed with evolocumab was much greater than its effects in GLAGOV (−2.29 vs −0.95%) [51] . The consistent finding of greater plaque regression in acute coronary syndrome patients was observed in the setting of greater plaque burden at baseline.…”
Section: Pcsk9 Inhibitorssupporting
confidence: 80%
“…Similar effects were observed throughout the length of the vessel and in prespecified lipid rich regions. A direct relationship was observed between changes in fibrous cap thickness and both achieved and changes in levels of LDL-C [51] . Similar findings were observed on serial OCT in PACMAN-AMI, in which alirocumab treated patients demonstrated a greater increase in fibrous cap thickness (+62.7 vs +33.2 μm) and decrease in macrophage arc (−26 vs −16°) [50] .…”
Section: Pcsk9 Inhibitorsmentioning
confidence: 81%
“…The results showed that in patients treated with statins, which already have a positive effect on inflammatory parameters, regardless of residual inflammation, an additional reduction in LDL cholesterol, without affecting inflammatory parameters with evolocumab, had a positive effect on reducing atherosclerotic plaque. These results were further confirmed by the High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS), which showed that evulocumab treatment increases the stability of the atherosclerotic bed by reducing the lipid core and increasing the fibrous cap thickness [40].…”
Section: Inflammationmentioning
confidence: 71%
“…Similar findings have been found in other studies [ 15 , 35 , 36 ]. Moreover, a recent study demonstrated that the combination of evolocumab and statin produced favorable changes in coronary atherosclerosis after non-ST-segment elevation myocardial infarction, consistent with stabilization or even regression [ 37 ].…”
Section: Discussionmentioning
confidence: 99%